Filing Details
- Accession Number:
- 0001209191-19-024175
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-04-09 18:59:06
- Reporting Period:
- 2019-04-05
- Accepted Time:
- 2019-04-09 18:59:06
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1662524 | Akcea Therapeutics Inc. | AKCA | Pharmaceutical Preparations (2834) | 472608175 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1692444 | Paula Soteropoulos | C/O Akcea Therapeutics, Inc. 22 Boston Wharf Road, 9Th Floor Boston MA 02210 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-04-05 | 30,000 | $6.48 | 30,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-04-05 | 30,000 | $32.11 | 0 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2019-04-08 | 1,787 | $6.48 | 1,787 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-04-08 | 1,787 | $32.17 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2019-04-05 | 30,000 | $0.00 | 30,000 | $6.48 |
| Common Stock | Stock Option (right to buy) | Disposition | 2019-04-08 | 1,787 | $0.00 | 1,787 | $6.48 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 1,712,866 | 2025-12-15 | No | 4 | M | Direct | |
| 1,711,079 | 2025-12-15 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- The weighted average sale price for the transaction reported was $32.1658, and the range of prices were between $32.11 and $32.20. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- The shares vest as follows: 1/4th of the shares vest one year after January 1, 2015;1/48th of the shares vest monthly thereafter over the next three years.
Billionaire Hedge Funds
